Patents by Inventor Jiancun Zhang

Jiancun Zhang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10919856
    Abstract: A cyclohexene compound and use thereof, which relates to the technical field of pharmaceutical chemistry is provided. The cyclohexene compound is the cyclohexene compound having a structural formula I or a pharmaceutically acceptable salt, an ester group prodrug or a stereoisomer thereof. It is verified by activity assay for influenza NA that the cyclohexene compound has a great inhibiting activity against both wild-typed and drug-resistant influenza viruses, and the inhibiting activity IC50 of some compounds against wild-typed and drug-resistant influenza viruses is lower than 5 nM, showing significant inhibiting effect on influenza viruses. This shows that the cyclohexene compound or a pharmaceutically acceptable salt or a stereoisomer thereof has superior application prospect on preparing anti-influenza drugs, thereby providing a new drug choice for treating influenza clinically.
    Type: Grant
    Filed: September 5, 2017
    Date of Patent: February 16, 2021
    Assignee: GUANGZHOU HENOVCOM BIOSCIENCE CO. LTD.
    Inventors: Jiancun Zhang, Kun Wang, Yan Liu, Deyao Li
  • Patent number: 10851068
    Abstract: A method for preparing a pyrimidone compound and an important intermediate in which raw materials of the preparation method are cheap, the reaction condition of preparation method is mild, the preparation method is simple to operate, and is safe and controllable, has high total yield, and thus is suitable for industrial production.
    Type: Grant
    Filed: July 3, 2018
    Date of Patent: December 1, 2020
    Assignee: SUNSHINE LAKE PHARMA CO., LTD.
    Inventors: Runfeng Lin, Xiaojun Wang, Jihua Lin, Liang Chen, Yingjun Zhang, Jiancun Zhang
  • Publication number: 20200246302
    Abstract: Provided are a long-acting prodrug of Rasagiline, which has application in the treatment of Central Nervous System diseases such as Parkinson's disease, preparation method and use thereof. The long-acting prodrug of Rasagiline has a structure of formula (I), wherein T is absent, or T is selected from each of R1 and R2 is independently selected from H, D, and alkyl; W is absent, or W is selected from (CH2)n, wherein n is an integer selected from 1 to 15; X is absent, or X is selected from (CH2)m, wherein m is an integer selected from 1 to 10; Y is absent, or Y is selected from —C(?O)NH—, —NHC(?O)—; R3 is selected from substituted or unsubstituted C1-C30 alkyl, substituted or unsubstituted C2-C30 alkenyl, substituted or unsubstituted C2-C30 alkynyl, substituted or unsubstituted C3-C30 cycloalkyl, cholane aliphatic group, —R3a—C(?O)O—R3b, —R3a—OC(?O)—R3b, —R3a—C(?O)NH—R3b, —R3a—NHC(?O)—R3b, —R3a—S(?O)1-2O—R3b and —R3a—OS(?O)1-2—R3b.
    Type: Application
    Filed: August 27, 2018
    Publication date: August 6, 2020
    Inventors: Jiancun ZHANG, Deyao LI, Yiqian ZHOU, Yiwu Wu
  • Publication number: 20200239513
    Abstract: Provided are a long-acting prodrug of Entecavir, preparation method and use thereof, wherein the prodrug of Entecavir has a structure of formula I. The prodrug of Entecavir can be released slowly, sustainably and steady, and converted to active compound of Entecavir to achieve a long-acting effect.
    Type: Application
    Filed: September 29, 2018
    Publication date: July 30, 2020
    Inventors: Jiancun ZHANG, Deyao LI, Yiqian ZHOU, Yiwu Wu, Yan LIU
  • Publication number: 20200157054
    Abstract: A method for preparing a pyrimidone compound and an important intermediate in which raw materials of the preparation method are cheap, the reaction condition of preparation method is mild, the preparation method is simple to operate, and is safe and controllable, has high total yield, and thus is suitable for industrial production.
    Type: Application
    Filed: July 3, 2018
    Publication date: May 21, 2020
    Applicant: NORTH & SOUTH BROTHER PHARMACY INVESTMENT COMPANY LIMITED
    Inventors: Runfeng LIN, Xiaojun WANG, Jihua LIN, Liang CHEN, Yingjun ZHANG, Jiancun ZHANG
  • Patent number: 10647682
    Abstract: Provided are salts of 2,6-dimethylpyrimidone derivatives and uses thereof. Also provided are pharmaceutical compositions containing the salts.
    Type: Grant
    Filed: July 19, 2017
    Date of Patent: May 12, 2020
    Assignee: NORTH & SOUTH BROTHER PHARMACY INVESTMENT COMPANY LIMITED
    Inventors: Runfeng Lin, Liang Chen, Xiaojun Wang, Yingjun Zhang, Jiancun Zhang
  • Patent number: 10494364
    Abstract: The invention relates to capthepsin K inhibitors and uses thereof, specifically relates to a class of compounds having the formula (I) which are used for treating or preventing cathepsin dependent diseases or conditions, specifically, wherein the cathepsin is capthepsin K. The compounds and compositions thereof can be used as bone resorption inhibitors for the treatment of associated diseases.
    Type: Grant
    Filed: August 26, 2016
    Date of Patent: December 3, 2019
    Assignees: SUNSHIN LAKE PHARMA CO., LTD, NORTH & SOUTH BROTHER PHARMACY INVESTMENT COMPANY LIMITED
    Inventors: Xiaojun Wang, Pingjian Zhou, Chuanwen Yang, Changwei Huang, Shaohui Xiong, Yingjun Zhang, Jiancun Zhang
  • Publication number: 20190308939
    Abstract: Provided are salts of 2, 6-dimethylpyrimidone derivatives and uses thereof. Also provided are pharmaceutical compositions containing the salts.
    Type: Application
    Filed: July 19, 2017
    Publication date: October 10, 2019
    Applicant: SUNSHINE LAKE PHARMA CO., LTD.
    Inventors: Runfeng LIN, Liang CHEN, Xiaojun WANG, Yingjun ZHANG, Jiancun ZHANG
  • Publication number: 20190241520
    Abstract: A cyclohexene compound and use thereof, which relates to the technical field of pharmaceutical chemistry is provided. The cyclohexene compound is the cyclohexene compound having a structural formula I or a pharmaceutically acceptable salt, an ester group prodrug or a stereoisomer thereof. It is verified by activity assay for influenza NA that the cyclohexene compound has a great inhibiting activity against both wild-typed and drug-resistant influenza viruses, and the inhibiting activity IC50 of some compounds against wild-typed and drug-resistant influenza viruses is lower than 5 nM, showing significant inhibiting effect on influenza viruses. This shows that the cyclohexene compound or a pharmaceutically acceptable salt or a stereoisomer thereof has superior application prospect on preparing anti-influenza drugs, thereby providing a new drug choice for treating influenza clinically.
    Type: Application
    Filed: September 5, 2017
    Publication date: August 8, 2019
    Inventors: Jiancun Zhang, Kun Wang, Yan Liu, Deyao Li
  • Publication number: 20190167593
    Abstract: A cyclohexene derivative or pharmaceutically acceptable salt thereof and application thereof, which belongs to the technical field of pharmaceutical technology is provided. The cyclohexene derivative of formula I or pharmaceutically acceptable salt thereof is a new broad-spectrum anti-influenza compound, having a great inhibiting effect on influenza viruses, specifically, it has a high activity to virus strains which is drug-resistant to Oseltamivir, and may be used as a broad-spectrum anti-influenza NA inhibitor effective to Tamiflu drug-resistance, for treating the flu caused by influenza viruses, thereby it is a broad-spectrum anti-influenza drug.
    Type: Application
    Filed: April 27, 2017
    Publication date: June 6, 2019
    Inventors: Jiancun Zhang, Deyao Li, Hong Li, Kun Wang, Yan Liu, Yan Wu, Xing Tang, Jianbo Song
  • Publication number: 20190002452
    Abstract: Provided is a modulator of FXR receptor and preparation and use thereof, which relates to the technical filed of medicinal chemistry. The embodiment provides a modulator of FXR receptor having a structural formula I or a pharmaceutically acceptable salt, stereoisomer, solvate or prodrug thereof, which can combine with FXR receptor (that is NR1H4) and be acted as a FXR agonist or a partial agonist for preventing and treating the disease mediated by FXR, such as chronic intrahepatic or extrahepatic cholestasis, hepatic fibrosis caused by chronic cholestasis or acute intrahepatic cholestasis, chronic hepatitis B, gallstone, hepatic carcinoma, colon cancer or intestinal inflammatory disease, etc. Specifically, for some chemical compounds, their EC50 for FXR agonist activity reach below 100 nM, which show an excellent FXR agonist activity and an excellent prospect to provide a new pharmaceutical selection in clinical treatment for the disease mediated by FXR.
    Type: Application
    Filed: December 22, 2016
    Publication date: January 3, 2019
    Inventors: Jiancun Zhang, Qingan ZOU, Yanwei Chen
  • Publication number: 20180303810
    Abstract: Provided are a nimodipine water-soluble derivative, and a preparation method and a use thereof, belonging to the field of pharmaceutical chemistry. The nimodipine water-soluble derivative has the structural feature of general formula I and has a relatively high water solubility, and can be converted into nimodipine by an internal enzyme in blood or in the body, so that the nimodipine water-soluble derivative can be used as a nimodipine prodrug and a calcium ion antagonist for treating cardiovascular and cerebrovascular diseases.
    Type: Application
    Filed: July 29, 2016
    Publication date: October 25, 2018
    Applicant: Guangzhou Henovcom Bioscience Co., Ltd.
    Inventors: Jiancun Zhang, Deyao Li, Kun Wang, Yan Liu, Yuanchao Zhang
  • Publication number: 20180230138
    Abstract: The invention relates to capthepsin K inhibitors and uses thereof, specifically relates to a class of compounds having the formula (I) which are used for treating or preventing cathepsin dependent diseases or conditions, specifically, wherein the cathepsin is capthepsin K. The compounds and compositions thereof can be used as bone resorption inhibitors for the treatment of associated diseases.
    Type: Application
    Filed: August 26, 2016
    Publication date: August 16, 2018
    Applicant: SUNSHINE LAKE PHARMA CO., LTD.
    Inventors: Xiaojun WANG, Pingjian ZHOU, Chuanwen YANG, Changwei HUANG, Shaohui XIONG, Yingjun ZHANG, Jiancun ZHANG
  • Patent number: 9951010
    Abstract: The compounds of Formula (I) which can be used as CRTH2 receptor antagonists are provided. The compounds of Formula (I) can be used in the treatment and prevention of asthma, allergic rhinitis and atopic dermatitis, as well as other diseases mediated by prostaglandin D2 (PGD2) at the CRTH2 receptor.
    Type: Grant
    Filed: September 11, 2015
    Date of Patent: April 24, 2018
    Assignee: SUNSHINE LAKE PHARMA CO., LTD.
    Inventors: Yingjun Zhang, Tianzhu Yu, Bing Liu, Xiangyu Zhang, Shiguo Zhang, Changchung Cheng, Jiancun Zhang
  • Patent number: 9902712
    Abstract: The present invention relates to the field of medicine, provided herein are novel nitrogenous heterocyclic compounds, their preparation methods and their uses as drugs, especially for treatment and prevention of tissue fibrosis. Also provided herein are pharmaceutically acceptable compositions comprising the nitrogenous heterocyclic compounds and the uses of the compositions in the treatment of human or animal tissue fibrosis, especially for human or animal renal interstitial fibrosis, glomerular sclerosis, liver fibrosis, pulmonary fibrosis, IPF, peritoneal fibrosis, myocardial fibrosis, dermatofibrosis, postsurgical adhesion, benign prostatic hyperplasia, skeletal muscle fibrosis, scleroderma, multiple sclerosis, pancreatic fibrosis, cirrhosis, myosarcoma, neurofibroma, pulmonary interstitial fibrosis, diabetic nephropathy, alzheimer disease or vascular fibrosis.
    Type: Grant
    Filed: December 19, 2014
    Date of Patent: February 27, 2018
    Assignee: SUNSHINE LAKE PHARMA CO., LTD.
    Inventors: Jiancun Zhang, Xiaojun Wang, Yingjun Zhang, Runfeng Lin, Yi Yu, Liang Chen, Jihua Lin
  • Patent number: 9802949
    Abstract: Provided are fused tricyclic compounds effective to inhibit the function of the NS5A protein of formula (I), wherein X, X?, Y, Y?, A, A?, Q1, Q2, R1-R4, X4, R5a, f and W are defined as in the description. Also provided herein are pharmaceutical compositions thereof, and uses in the manufacture of a medicament for treating HCV infection or a HCV disorder thereof.
    Type: Grant
    Filed: November 28, 2013
    Date of Patent: October 31, 2017
    Assignee: SUNSHINE LAKE PHARMA CO., LTD.
    Inventors: Yingjun Zhang, Jiancun Zhang, Hongming Xie, Qingyun Ren, Shifeng Li, Changping Fu, Bailin Hu, Xiwei Wu, Changhua Tang
  • Publication number: 20170267634
    Abstract: The compounds of Formula (I) which can be used as CRTH2 receptor antagonists are provided. The compounds of Formula (I) can be used in the treatment and prevention of asthma, allergic rhinitis and atopic dermatitis, as well as other diseases mediated by prostaglandin D2 (PGD2) at the CRTH2 receptor.
    Type: Application
    Filed: September 11, 2015
    Publication date: September 21, 2017
    Applicant: SUNSHINE LAKE PHARMA CO., LTD.
    Inventors: Yingjun ZHANG, Tianzhu YU, Bing LIU, Xiangyu ZHANG, Shiguo ZHANG, Changchung CHENG, Jiancun ZHANG
  • Patent number: 9738629
    Abstract: Provided herein is a bridged bring compound of formula (I) or a stereoisomer, a tautomer, an N-oxide, a hydrate, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof, which can be used for treating treat hepatitis C virus C(HCV) infection or hepatitis C disease. Furthermore provided herein are pharmaceutical compositions containing the compounds and the method of using the compounds or pharmaceutical compositions thereof in the treatment of HCV infection or hepatitis C.
    Type: Grant
    Filed: January 22, 2015
    Date of Patent: August 22, 2017
    Assignee: SUNSHINE LAKE PHARMA CO., LTD.
    Inventors: Yingjun Zhang, Hongming Xie, Jiancun Zhang, Bailin Hu, Qinghong Fang, Qingyun Ren
  • Publication number: 20170044140
    Abstract: Provided herein is a bridged bring compound of formula (I) or a stereoisomer, a tautomer, an N-oxide, a hydrate, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof, which can be used for treating treat hepatitis C virus (HCV) infection or hepatitis C disease. Furthermore provided herein are pharmaceutical compositions containing the compounds and the method of using the compounds or pharmaceutical compositions thereof in the treatment of HCV infection or hepatitis C.
    Type: Application
    Filed: January 22, 2015
    Publication date: February 16, 2017
    Applicant: SUNSHINE LAKE PHARMA CO., LTD.
    Inventors: Yingjun ZHANG, Hongming XIE, Jiancun ZHANG, Bailin HU, Qinghong FANG, Qingyun REN
  • Patent number: 9556191
    Abstract: Provided herein are aminoquinazoline compounds, salts and uses thereof. The compounds have Formula (I), or a stereoisomer, a geometric isomer, a tautomer, an N-oxide, a hydrate, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof. Also provided herein are pharmaceutical compositions containing the compounds disclosed herein, and uses of the compounds or the compositions for preventing, managing, treating or lessening the severity of a proliferative disorder in a patient and for modulating the protein tyrosine kinase activity.
    Type: Grant
    Filed: April 28, 2014
    Date of Patent: January 31, 2017
    Assignee: SUNSHINE LAKE PHARMA CO., LTD.
    Inventors: Yingjun Zhang, Bing Liu, Jinlei Liu, Jiancun Zhang, Changchung Cheng